 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Lamprene |
| Other names | N,5-bis(4-chlorophenyl)-3-(1-methylethylimino)-5H-phenazin-2-amine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682128 |
| Routes of administration | By mouth |
| Drug class | Phenazine dye[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 70 days |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C27H22Cl2N4 |
| Molar mass | 473.396 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 210 to 212 °C (410 to 414 °F) |
| |
| |
  (what is this?) (verify) | |
Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy.[1] It is specifically used for multibacillary (MB) leprosy and erythema nodosum leprosum.[3] Evidence is insufficient to support its use in other conditions.[1] It is taken by mouth.[1]
Common side effects include abdominal pain, diarrhea, itchiness, dry skin, and change in color of the skin.[1] May also cause swelling of the lining of the gastrointestinal tract, increased blood sugar, and sensitivity to the sun.[3] It is unclear if use during pregnancy is safe.[1] Clofazimine is a phenazine dye and believed to work by interfering with DNA.[1]
Clofazimine was discovered in the 1950s at Trinity College, Dublin,[4] and approved for medical use in the United States in 1986.[1] It is on the World Health Organization's List of Essential Medicines.[5] The wholesale cost in the developing world is about US$24 per month.[6] In the United States it is not available commercially but can be obtained from the US Department of Health and Human Services.[1]
References
edit- ^ a b c d e f g h i j k "Clofazimine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ^ Cite error: The named reference
whowas invoked but never defined (see the help page). - ^ a b World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 132. hdl:10665/44053. ISBN 9789241547659.
- ^ Greenwood, David (2008). Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. OUP Oxford. p. 200. ISBN 9780199534845. Archived from the original on 2021-08-28. Retrieved 2019-07-31.
By 1954 related molecules known as iminophenazines were being investigated... one of the first ones to be made, originally given the laboratory code B663 ... B663—subsequently called clofazimine
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Clofazimine". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.